th 6
Thursday 24thJune 2021 16:00-18:20
This promotional webinar is organised to provide educational sessions for healthcare professionals working in Haematology, to raise awareness of rare diseases and learn about conditions that feature low platelets and their differential diagnosis. The webinar will explore common causes from rare disorders, macrophage activation syndrome, and ruling rare conditions out as a differential diagnosis, delivered by expert medical speakers.
This meeting is initiated and funded by Takeda. This meeting is for UK healthcare professionals only. Takeda representatives will be present at the meeting and Takeda products will be discussed. This meeting will be recorded.
VPRIV (velaglucerase alfa) is indicated for long-term enzyme replacement therapy (ERT) in patients with type 1 Gaucher disease. Click here for prescribing information for VPRIV OBIZUR▼ (susoctocog alfa) is indicated for the treatment of bleeding episodes in patients with acquired haemophilia caused by antibodies to factor VIII. OBIZUR is indicated in adults. Click here for prescribing information for OBIZUR
VEYVONDI▼(vonicog alfa) is indicated in adults (age 18 and older) with von Willebrand disease (VWD), when desmopressin (DDAVP) treatment alone is ineffective or not indicated, for the treatment of haemorrhage and surgical bleeding and prevention of surgical bleeding. VEYVONDI should not be used in the treatment of Haemophilia A. Click here for prescribing information for VEYVONDI
FEIBA (factor VIII inhibitor bypassing activity) is indicated for treatment of spontaneous bleeding and cover of surgical interventions in haemophilia A patients with factor VIII inhibitors and in non-haemophiliacs with acquired factor VIII inhibitors. Prophylaxis in haemophilia A patients with high responding inhibitors and frequent joint bleeding. Click here for prescribing information for FEIBA
Adverse events should be reported. Reporting forms and information can be found at https:// yellowcard.mhra.gov.uk/ Adverse events should also be reported to Takeda UK Ltd at: [email protected]. AGENDA
16:00– 16:10 Welcome and introduction Professor Derralynn Hughes, Clinical Director of Haematology and Oncology, Royal Free Hospital, and Professor in Haematology at University College London
16:10– 16:30 Rare clotting abnormalities Dr Keith Gomez, Haemophilia Centre and Thrombosis unit, Royal Free Hospital
Approach to thrombocytopenia, flagging rare but serious 16:30– 16:45 conditions Dr Sateesh Nagumantry, Consultant Haematologist, Associate Divisional director (Pathology), Peterborough City Hospital, PNH Network Physician, Peterborough
16:45– 17:05 BREAK
17:05– 17:20 HaemSTAR- How does the HaemSTAR UK network of trainee haemotologists work to promote non-malignant haematology research? Dr Phillip Nicolson, Speciality Registrar in Clinical Haematology, University Hospitals of Birmingham NHS Foundation Trust
17:20– 17:35 Haemophagocytic lymphohistiocytosis (HLH), macrophage activation syndromes Professor Matt Collin, Professor of Haematology and Honorary Consultant Haematologist, Newcastle upon Tyne Hospitals NHS Foundation Trust
17:35– 17:50 Immune thrombocytopenic purpura (ITP) and differential Diagnosis Dr Nichola Cooper, Clinical Senior Lecturer and Honorary Consultant Haematologist, Imperial College London, Imperial College Healthcare NHS Trust
17:50– 18:20 Open Discussion Facilitated by Professor Derralynn Hughes If you would like to register for this meeting please email [email protected]
C-APROM/UK/VPR/0003 Date of preparation: April 2021 Copyright (©) 2021 Takeda Pharmaceutical Company Ltd This event has been accredited 2 CPD points.